NCT04237129View on ClinicalTrials.gov

PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 27, 2019

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Gan & Lee Insulin Aspart

All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.

Trial Locations (1)

D-55116

Profil Mainz GmbH & Co. KG, Mainz

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY